For over a decade, Institut Pasteur Korea has focused on technology development to build the best drug discovery platform for high-content screening performed in BSL level 2 and 3 environments.
Institut Pasteur Korea's Discovery Chemistry group applies new concepts of drug design to optimize hit-to-lead identification.